menu

NEWS

Walking speeds of multiple sclerosis patients, as measured by the Echo5D Ambient Measurement System, showed strong agreement with two clinical “gold standards”

Atlas 5D is pleased to report that its Ambient Measurement System, Echo5D, produces similar results as two clinical gold standards of gait measurement in multiple sclerosis patients. The Echo5D allows for convenient in-home measurement. Walking speed is an important measure of gait impairment in multiple sclerosis (MS). The clinical assessment of walking speed requires dedicated time, space, and personnel, and may not accurately gauge real-world performance. The term “Ambient Measurement System” (AMS) refers to a new class of device that passively measures walking speed at home, without the need for dedicated space or specialized setup. This study compared an AMS,...

READ MORE
Atlas5D’s Ambient Measurement System (AMS), Echo5D, selected to support Solid Biosciences gene-transfer clinical trial

Atlas5D is proud to announce that Solid Biosciences will utilize the company’s 24×7 real-world mobility and behavioral measurements as part of “Ignite DMD”, a phase I/II gene transfer study to investigate the safety, tolerability, and efficacy of intravenous SGT-001 in patients with Duchenne muscular dystrophy (DMD). Atlas5D’s Ambient Measurement System (AMS), dubbed Echo5D, will be placed into each patient’s home to help quantify treatment response. Jorge Quiroz, MD, Chief Medical Officer of Solid Biosciences, said, “In the past, there has been no technology that could effectively measure clinically relevant movements in a person’s own home, without the requirement for wearables,...

READ MORE
BGI, Hummingbird Diagnostics to Develop miRNA Tests for Neurodegenerative Disorders

Dec 06, 2017 | staff reporter NEW YORK (GenomeWeb) – BGI of China and Hummingbird Diagnostics of Germany have signed a memorandum of understanding to collaborate on miRNA-based molecular diagnostic applications using next-generation sequencing technology, in particular in the areas of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease. Under the agreement, the partners will use Hummingbird’s miRNA database and expertise in sample preparation as well as BGI’s BGISEQ sequencer and analysis pipeline to develop targeted miRNA in vitro diagnostic assays for Alzheimer’s, Parkinson’s, and other diseases. In addition, the firms will collaborate in the areas of wellness, fitness, and...

READ MORE
Ceres Nanosciences announces plans for significant growth in Prince William County, Virginia

Prince William County, VA – December 12, 2017 – Ceres Nanosciences (Ceres) is pleased to announce its recent expansion in Prince William County, Virginia. Following a successful fundraising round in 2017, Ceres has rapidly expanded both its staff and its facilities to accommodate the growing demand for the novel Nanotrap® particle platform across the life sciences industry. The Nanotrap® particle provides enhanced sample processing capabilities to new and existing diagnostic tests for some of the most challenging diseases and conditions, such as Lyme disease, respiratory diseases, emerging infectious diseases and cancer detection, as well as for improved health and wellness monitoring....

READ MORE
The Managers of GreyBird Ventures Partner with JF Healthcare in China

China, the world’s second largest and fastest growing market for healthcare products and services, cannot be ignored in the plans for any medical technology enterprise. It is a country where doing business as a foreign entity can be both highly complex and fraught with potential pitfalls. Therefore, the managers of GreyBird Ventures have decided to partner with a trusted enterprise, JiuFeng Healthcare (JF), to provide advice, assistance, and access to the Chinese market both for our firm and our portfolio companies. The GreyBird Managers have enjoyed a decades-long trustful relationship with the Founder, Chairman, and CEO of JF, Frank Wu...

READ MORE
Hummingbird Diagnostics GmbH and Saarland University Collaborate in Early Disease Detection Based on Molecular Markers: miRNA Experts Sign Framework Agreement

HEIDELBERG and SAARBRÜCKEN, November 14, 2017 – Hummingbird Diagnostics GmbH, specialized in early disease detection using molecular markers derived from blood, and Saarland University agreed on a comprehensive framework agreement regarding an expanded collaboration in the field of molecular diagnostics. The work aims at the validation of miRNA biomarkers in blood samples, allowing for an early detection of common serious diseases including lung cancer, chronic obstructive lung disease (COPD), Alzheimer’s and Parkinson’s. The project partners at Saarland University are the Department of Human Genetics and the Chair of Clinical Bioinformatics. Hummingbird Diagnostics has been maintaining long-standing research collaborations with both...

READ MORE
1 2 3

GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER